Measurement of Gastric Residual Volume via Ultrasound after Receiving Intravenous Ondansetron, Metoclopramide, and Neostigmine in Critically Ill Patients: A Double-Blind Clinical Trial

• Published in: Tanaffus 2021-04, Vol.20 (4), p.312-318
• Main Authors: Farzanegan, Behrooz, Shafigh, Navid, Heshmatnia, Jalal, Hashemian, Seyed Mohammadreza, Malekshoar, Mehran, Afzal, Golnaz, Jamaati, Hamidreza, Kazempour-Dizaji, Mehdi, Fathi, Mohammad
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1735-0344; 2345-3729

BackgroundGastric residual volume (GRV) is considered an important parameter for gastric emptying and nutrition tolerance. This volume is measured before any nutrition and has a direct effect on the volume and timing of the next nutrition. The present study aimed to examine the GRV via ultrasound after receiving intravenous ondansetron, metoclopramide, and neostigmine. Materials and MethodsIn the present study, 40 patients were included in the study, 10 patients were excluded from the study due to death during treatment, and 30 patients were divided into three groups of 10(10 patients in each group).The first, second, and third groups received 2.5, 10, and 8 mg neostigmine, metoclopramide, and ondansetron every 8 h, respectively. The drugs were infused as a micro set in 100 ml normal saline into patients within 30 min. The patients underwent ultrasound imaging and GRV measurement by an intensive care unit (ICU) subspecialty fellow, who was not aware of the drugs received by the patients, in the 1st h of hospitalization, 6 h after drug injection, and once daily for 4 days. ResultsA total of 40 patients entered the study based on inclusion and exclusion criteria. The effect of neostigmine on reducing GRV (Gastric residual volume) in ICU patients was better than those of the other two drugs, which was significant. ConclusionThe results of this study showed that neostigmine has a better and significant effect on reducing GRV in ICU patients, compared to those of ondansetron and metoclopramide.